Fed Circuit rejects Cellect rehearing on double patenting
En banc petition concerning obviousness-type double-patenting rejected by the Court of Appeals | Decision on patent term adjustment has been closely followed by pharma companies, NYIPLA, and AIPLA.
Source: worldipreview.com